INDIANAPOLIS, May 29, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data showing that FORTEO significantly increased lumbar spine volumetric bone mineral density (vBMD) ...
SAN DIEGO, Sept. 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented a study that assessed the effects of 18 months of treatment with FORTEO ® (teriparatide [rDNA origin] ...
Forteo (teriparatide) is a brand-name drug that doctors prescribe for some people with osteoporosis. It contains proteins that strengthen bones and stimulate new bone growth. A typical prescription is ...
INDIANAPOLIS, Oct. 15, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented data comparing the effects of FORTEO and zoledronic acid on transiliac crest bone biopsies at six months ...
Please provide your email address to receive an email when new articles are posted on . Forteo promotes rapid bone formation in the femoral neck, with pronounced effects in cancellous and endocortical ...
Eli Lilly and Co. has won U.S. regulatory approval to market its slow-selling osteoporosis drug Forteo for a new use, Lilly announced today. Lilly can now promote Forteo as a therapy for men and women ...
The FDA has approved its NDA for PF708 under the 505(b)(2) regulatory pathway, with Amgen, Inc. AMGN's Forteo as the reference drug. PF708 has been indicated to treat osteoporosis in certain patients ...
DUBLIN--(BUSINESS WIRE)--The "Forteo - API Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Forteo - API Insight, 2019 provides product and API manufacturers' details ...
Pfenex has received the Food and Drug Administration’s blessing for PF708. The product uses Forteo (teriparatide injection) as a reference drug, and like Forteo is indicated for the treatment of ...
The osteoporosis drug Forteo may be trumping its category competition. In a study developed by the University of Alabama at Birmingham, researchers concluded that Forteo prevented fractures in ...
Eli Lilly and Company LLY today presented data comparing the effects of FORTEO and zoledronic acid on transiliac crest bone biopsies at six months in postmenopausal women with osteoporosis, based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback